Antigen selection is important for vaccines' efficacy. A comparison of two dendritic cell-based vaccination strategies showed that peptide vaccines using neoantigens predicted on the basis of in silico peptide-MHC binding affinity do not perform well compared to whole-tumor-lysate vaccines. However, prioritizing tumor-rejecting neoepitopes based on effective in vitro peptide-MHC binding affinity and peptide immunogenicity leads to more effective vaccines.
Antigen selection and prioritization represent crucial determinants of vaccines' efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effec-tive in vitro peptide-MHC binding affinity and peptide immunogenicity signifi-cantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据